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Objectives The purpose of this study was to evaluate the incidence of vascular complications and
the predictors of Prostar failure for a “true percutaneous approach” in transfemoral transcatheter
aortic valve implantation (TAVI).
Background Safety and efﬁcacy of a true percutaneous approach in transfemoral-TAVI has not been
described in a large prospective cohort.
Methods Among 264 patients included in our prospective TAVI database (October 2006 to Decem-
ber 2010), transfemoral-TAVI was performed in 170 patients. True percutaneous approach was per-
formed in 142 consecutive patients since March 2008. Successful closure with Prostar was deﬁned as
adequate hemostasis without Prostar-related vascular complications. We compared the incidence of
vascular complications in our early and late experience.
Results Patients were 83.0  7.2 years old and with a EuroSCORE of 24.0  11.6%. The Edwards
valve (Edwards Lifesciences, Irvine, California) (18- to 24-F) was used in 109 cases and the CoreValve
(Medtronic, Minneapolis, Minnesota) (18-F) in 31. The sheath outer diameter to minimal femoral di-
ameter ratio (SFAR) was 0.96  0.14. Successful closure was achieved in 90.7%, and was signiﬁcantly
increased (95.7% vs. 85.7%, p  0.047) in the late experience group. Cross-over to surgery was re-
quired in 3.6%. Vascular complications occurred in 20.0%, and were signiﬁcantly lower in the late
experience group (11.4% vs. 28.6%, p  0.012). Major vascular complications (2.9% vs. 14.3%, p 
0.018) were decreased in the late experience group. Early experience (hazard ratio [HR]: 3.66, 95%
conﬁdence interval [CI]: 1.04 to 13.89, p  0.047) and SFAR (HR: 110.80, 95% CI: 1.15 to
10,710.73, p  0.044) predicted Prostar failure by univariate analysis.
Conclusions Experience reduced major vascular complications in a true percutaneous approach for
transfemoral-TAVI. Further application of this less invasive strategy is feasible and may be beneﬁcial,
in this high-risk patient cohort. (J Am Coll Cardiol Intv 2012;5:207–14) © 2012 by the American
College of Cardiology Foundation
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208Transcatheter aortic valve implantation (TAVI) has emerged as
a new therapeutic option for patients with severe symptom-
atic aortic stenosis (AS), who are ineligible or high risk for
conventional surgical aortic valve replacement (1,2). More
than 30,000 procedures have been performed worldwide
since 2002, and the technique is now reaching relative
maturity.
Transfemoral-TAVI represents the most widely used and
least invasive approach (3). Initially, surgical arteriotomy
was required for femoral artery access and closure; however,
this technique has several disadvantages, including the
necessity for general or spinal anesthesia, prolonged proce-
dure duration, and increased post-procedure morbidity (4).
More recently, a true percutaneous approach to transfemoral-
TAVI using the Prostar XL vascular closure system (Abbott
Vascular, Santa Clara, California) has been performed. This
device has been successfully used during endovascular aortic
aneurysm repair for decades (5–11),
and avoids many of the potential
complications associated with surgi-
cal cutdown. Nevertheless, this
minimally invasive technique may
be associated with significant
complications (3,12,13). Indeed,
there is a paucity of evidence de-
tailing the efficacy of the Prostar
XL in TAVI populations, and the
factors that predict device failure
have not been described.
The objectives of this study
were to describe vascular com-
plications in a large prospective
cohort of transfemoral-TAVI
patients who underwent a true
percutaneous approach with the
Prostar XL device, to identify
the predictors of failure, and to
evaluate the role of experience in the use of this device.
Methods
Study population and design. From October 2006, consec-
utive high-risk patients with symptomatic severe AS treated
with TAVI at our institution were prospectively included in
our TAVI database. Patients with symptomatic severe AS
(valve area 0.8 cm2) were considered candidates for TAVI
if they had a logistic European System for Cardiac Opera-
tive Risk Evaluation score (EuroSCORE) 20%, if surgery
was deemed to be of excessive risk due to significant
comorbidities, or if other risk factors not captured by these
scoring systems (e.g., porcelain aorta) were present. The
decision to proceed with TAVI was discussed by a dedicated
Abbreviations
and Acronyms
ACT  activated clotting
time
AS  aortic stenosis
BMI  body mass index
CI  confidence interval
HR  hazard ratio
MLD  minimal lumen
diameter
MSCT  multislice
computed tomography
SFAR  sheath to femoral
artery ratio
TAVI  transcatheter aortic
valve implantation
VARC  Valve Academic
Research Consortiumheart team, which included experienced clinical and inter- sventional cardiologists, cardiovascular surgeons, and anes-
thesiologists. All patients selected for TAVI underwent
screening physical examination, transthoracic and trans-
esophageal echocardiography, baseline laboratory indexes,
and coronary angiography. Assessment of the iliofemoral
vessels was performed by selective iliofemoral angiography
from 2 orthogonal planes. Multislice computed tomography
(MSCT) of the iliofemoral vasculature was also recom-
mended.
Between October 2006 and December 2010, a total of
264 patients were included in our prospective TAVI data-
base. One hundred seventy consecutive patients underwent
transfemoral-TAVI. Vascular access was achieved by surgi-
cal cutdown in the first 28 cases. From March 2008, a true
percutaneous approach using the Prostar XL was performed
for all transfemoral-TAVI procedures. These 142 cases are
the subject of the current investigation. All patients con-
sented to study participation.
Procedures. Before TAVI, all patients were taking aspirin
160 mg) and clopidogrel (75 mg) daily, or were given a
oading dose of clopidogrel (300 to 600 mg). A bolus of
ntravenous heparin (70 IU/kg) was administered at the
tart of each procedure to achieve an activated clotting time
ACT) of 250 to 300 s, and the ACT was measured every
0 min thereafter.
The Prostar XL suture-mediated vascular closure system
s composed of a 0.038-inch guidewire-compatible hydro-
hilic introducer sheath, which contains 2 pairs of nitinol
eedles that are deployed from inside the arteriotomy, and
braided polyester sutures, a needle guide, and a rotating
arrel precisely controlling the needles during device de-
loyment (5). The true percutaneous technique for TAVI,
ith pre-closure of the femoral artery access site using the
rostar XL device, has been previously described (5,11). In
rief, puncture of the anterior wall of the common femoral
rtery was ensured by selective iliofemoral angiography from
he contralateral side. After dilation of the tract to the
emoral artery with an 8-F dilator, the Prostar is advanced
ver a 0.035-inch guidewire and deployed (14). The device
s deployed, and the sutures are secured with mosquito
lamps. A single Prostar XL was used to close arteriotomies
or 18- to 19-F sheaths and 2 for 22- and 24-F sheaths at
45° angle.
After femoral artery pre-closure, the introducer sheath is
arefully inserted over a stiff guidewire, and the valve
ubsequently deployed. The technical aspects of the aortic
alve implantation have been previously described in detail
15–17), and are not the subject of this study. Following
alve deployment, the introducer sheath is retracted to the
evel of the external iliac artery, and selective angiography is
erformed to assess for iliac artery complications. Thereaf-
er, the sheath is removed over the stiff guidewire and the
emoral arteriotomy sealed by advancing the white Prostar
uture to the artery with the knot pusher. The guidewire
o
o
m
b
(
M
w
g
m
c
w
a
r
f
a
d
p
S

a
s
fi
t
a
t
(
s
a
i
i
p
t
w
s
c
e
C
h
f
s
p
h
d
(
i
(
r
s
p
i
t
r
a
i
d
o
c
d
i
d
f
e
p
e
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 2 , 2 0 1 2 Hayashida et al.
F E B R U A R Y 2 0 1 2 : 2 0 7 – 1 4 True Percutaneous Approach in Transfemoral-TAVI
209remains in situ until significant adequate hemostasis is
obtained. The guidewire is then gently removed, and the
green suture is tightened; a final iliofemoral angiogram is
performed from the contralateral side to ensure femoral
artery closure and assess for vascular complications.
Vascular assessment. Quantitative angiography of the fem-
ral, external iliac, and common iliac arteries was performed
ffline after calibration with a contrast-filled catheter. All
easurements and qualitative assessment were performed
y 2 independent operators. The minimal lumen diameter
MLD) of the iliofemoral arteries was also measured by
SCT where possible. Vessel tortuosity and calcifications
ere evaluated as previously described (18). Tortuosity was
raded: 0  no tortuosity; 1  mild (30° to 60°); 2 
oderate (60° to 90°); and 3  severe (90°). Arterial
alcification was evaluated by fluoroscopy or by MSCT, and
as graded: 0  no calcification; 1  mild; 2  moderate;
nd 3  severe.
The sheath to femoral artery ratio (SFAR) defines the
atio between the sheath outer diameter (mm) and the
emoral artery MLD (mm) (3). The sheath to external iliac
rtery ratio was defined as the ratio between sheath outer
iameter (mm) and external iliac MLD (mm).
On the basis of the results of our previous study (3), we
erformed transfemoral-TAVI in patients who had an
FAR of 1.0 in calcified femoral arteries, and an SFAR
1.1 in noncalcified arteries. Thus, the minimal femoral
rtery diameter required for the 19- and 18-F introducer
heaths was 6.8 mm and 6.5 mm, respectively, in noncalci-
ed iliofemoral vessels, and 7.5 mm and 7.2 mm, respec-
ively, in calcified iliofemoral arteries. If femoral arterial
ccess was deemed unsuitable for transfemoral TAVI,
ransapical TAVI was performed with the Edwards valve
Edwards Lifesciences, Irvine, California), or trans-
ubclavian TAVI with the CoreValve (Medtronic, Minne-
polis, Minnesota).
Treatment of vascular complications. Management of vas-
cular complications was left to the operators’ discretion.
Usually, iliofemoral dissections or stenoses were treated
with conventional balloon angioplasty or, if necessary,
balloon-expandable or self-expandable stents. Small ilio-
femoral perforations, insufficiently managed with manual
compression or balloon angioplasty, were treated with
covered stents, and vessel ruptures were managed emer-
gently with temporary balloon angioplasty and covered
stents or emergency surgery if percutaneous therapy failed.
Post-procedural care. All patients were observed in the
ntensive care unit for at least 24 h after Edwards valve
mplantation and 72 h after CoreValve implantation (in
atients without previous pacemakers). Dual antiplatelet
herapy was continued for 6 months, and thereafter, aspirin
as continued indefinitely.
Endpoint deﬁnitions. The main endpoints of this study were
uccessful closure with Prostar, vascular complications, all-ause mortality at 30 days, and a 30-day safety composite
ndpoint, as defined by the Valve Academic Research
onsortium (VARC) criteria (19).
Successful closure with Prostar was defined as adequate
emostasis without any interventional or surgical correction
or Prostar-related vascular complication.
Major vascular complications were defined as: 1) access
ite or access-related vascular injury (dissection, stenosis,
erforation, rupture, arteriovenous fistula, pseudoaneurysm,
ematoma, irreversible nerve injury, or compartment syn-
rome) leading to either death, significant blood transfusion
4 U), unplanned percutaneous or surgical intervention, or
rreversible end-organ damage; and 2) distal embolization
noncerebral) from a vascular source requiring surgery or
esulting in amputation or irreversible end-organ damage.
Minor vascular complications were defined as: 1) access
ite or access-related vascular injury not requiring unplanned
ercutaneous or surgical intervention and not resulting in
rreversible end-organ damage; 2) distal embolization
reated with embolectomy and/or thrombectomy and not
esulting in amputation or irreversible end-organ damage;
nd 3) failure of percutaneous access site closure resulting in
nterventional or surgical correction and not associated with
eath, significant blood transfusions, or irreversible end-
rgan damage.
The combined 30-day safety endpoint included: 1) all-
ause mortality; 2) major stroke; 3) life-threatening (or
isabling) bleeding; 4) acute kidney injury—stage 3 (includ-
ng renal replacement therapy); 5) periprocedural myocar-
ial infarction; 6) major vascular complication; and 7) a
urther intervention due to valve dysfunction.
To evaluate the impact of the learning curve on the study
ndpoints, the first 70 true percutaneous TAVI cases
erformed at our institution defined the “early center
xperience group.”
Statistical analysis. Quantitative variables are expressed as
mean  SD and qualitative variables as number and
percentage. Comparison of quantitative variables was per-
formed with an unpaired Student t test or Wilcoxon rank
sum test, depending on variable distribution. The chi-
square test or Fisher exact test was used to compare
qualitative variables. Univariate logistic regression analysis
was performed to identify the predictors of Prostar failure.
A stepwise logistic regression analysis, including all variables
with p values0.1 in the univariate analysis, was performed
to determine the predictors of major complication. Statis-
tical significance was defined as p  0.05. The data were
analyzed with PASW Statistics 17.0 (SPSS, Chicago,
Illinois).
Results
Between March 2008 and December 2010 or March, 142
consecutive patients attending for transfemoral-TAVI un-
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210derwent the true percutaneous approach. Two patients were
excluded from the current analysis; 1 because of failed
vascular access, and the second due to aortic rupture before
TAVI implantation. The remaining 140 patients success-
fully received either the Edwards valve (n  109) or the
oreValve Revalving system (n  31).
Patient characteristics. The clinical characteristics of the
tudy population and the early and late experience groups
re presented in Table 1. The mean age was 83.0  7.2
ears, 51.4% were female, and 21.4% had diabetes mellitus.
ongestive heart failure class III/IV was prevalent in 84.3%,
oronary artery disease in 61.4%, peripheral arterial disease in
6.4%, and 61.4% of patients had significant renal dysfunction
estimated glomerular filtration rate 60 ml/min). The mean
ogistic EuroSCORE was 24.0  11.6%.
In the early experience group, patients had a higher
ncidence of New York Heart Association functional class
II/IV heart failure (95.7% vs. 72.9%, p  0.001), lower left
entricular ejection fraction (45.8  13.1% vs. 54.3 
4.2%, p  0.001), poorer renal function (estimated glo-
erular filtration rate: 45.0  19.1 ml/min vs. 61.6  33.1
ml/min, p  0.001), and a higher logistic EuroSCORE
(26.9  11.8% vs. 21.1  10.7%, p  0.003).
Table 1. Baseline Characteristics of the Study Population
Total
(N140)
Early
Experience
(n70)
Late
Experience
(n70)
p
Value
Age, yrs 83.0 7.2 83.5 5.7 82.4 8.4 0.379
Female 72 (51.4%) 35 (50.0%) 37 (52.9%) 0.739
BMI, kg/m2 25.7 4.3 25.3 3.8 26.2 4.8 0.208
Diabetes 30 (21.4%) 15 (21.4%) 15 (21.4%) 1.000
Hyperlipidemia 62 (44.3%) 31 (44.3%) 31 (44.3%) 1.000
Hypertension 102 (72.9%) 53 (75.7%) 49 (70.0%) 0.569
Current smoker 4 (2.9%) 3 (4.3%) 1 (1.4%) 0.620
NYHA functional class III/IV 118 (84.3%) 67 (95.7%) 51 (72.9%) 0.001
Coronary artery disease 86 (61.4%) 47 (67.1%) 39 (55.7%) 0.224
Previous MI 14 (10.0%) 7 (10.0%) 7 (10.0%) 1.000
Previous PCI 45 (32.1%) 28 (40.0%) 17 (24.3%) 0.070
Previous CABG 20 (14.3%) 10 (14.3%) 10 (14.3%) 1.000
Peripheral artery disease 37 (26.4%) 20 (28.6%) 17 (24.3%) 0.573
Cerebrovascular disease 14 (10.0%) 7 (10.0%) 7 (10.0%) 1.000
COPD 50 (35.7%) 21 (30.0%) 29 (41.4%) 0.217
eGFR, ml/min 53.8 28.6 45.0 19.1 61.6 33.1 0.001
eGFR 60 ml/min 86 (61.4%) 48 (68.6%) 38 (54.3%) 0.118
eGFR 30 ml/min 22 (15.7%) 13 (18.6%) 9 (12.9%) 0.366
Logistic EuroScore, % 24.0 11.6 26.9 11.8 21.1 10.7 0.003
LVEF, % 50.1 14.3 45.8 13.1 54.3 14.2 0.001
LVEF 40% 45 (32.1%) 28 (40.0%) 17 (24.3%) 0.070
Values are mean SD or n (%).
BMI  body mass index; CABG  coronary artery bypass graft; COPD  chronic obstructive
pulmonary disease; eGFR estimated glomerular filtration rate; LVEF left ventricular ejection
fraction; MI myocardial infarction; NYHA  New York Heart Association; PCI  percutaneouscoronary intervention.Procedural characteristics. The procedural characteristics of
he study population in the early and late experience groups
re presented in Table 2.
The Edwards valve was used in 77.9% of the cohort, and
eneral anesthesia was performed in 28.6%. The 18- or
9-F introducer sheaths were used in 70.7% of cases, and
he mean external diameter of the sheath used was 7.72 
.83 mm. The average femoral artery MLD was 8.16 
.31 mm, and SFAR 0.96  0.14. The mean MLD of
ommon and external iliac artery was 10.45 2.30 mm and
.76  1.56 mm, respectively. An average of 1.30  0.49
rostar XL devices were used per procedure, and the mean
rocedure time was 75.3  25.7 min.
With increasing center experience, the use of local anes-
hesia increased (97.1% in the late vs. 47.1% in the early
xperience, p 0.001). In parallel, device development over
he course of the study resulted in smaller sheath sizes (7.28 
.55 mm vs. 8.15 0.80 mm, p 0.001), a smaller femoral
rtery MLD (7.94  1.40 vs. 8.38  1.19, p  0.052), and
trend toward a decreased SFAR (0.94  0.16 vs. 0.99 
.12, p  0.068). There was also a reduction in the number
f Prostar XL devices deployed (1.00 0.17 vs. 1.59 0.52,
 0.001) and the total procedure time (71.3  23.9 min vs.
1.5  27.4 min, p  0.049).
Vascular complications. Any vascular complications oc-
urred in 28 patients, which represent 20.1% of the entire
ohort (Table 3). Major vascular complications occurred in
2 cases (8.6%) and minor complication in 16 (11.4%).
ncreased center experience was associated with a significant
eduction in the incidence of any vascular complications
11.4% vs. 28.6%, p  0.012) and major complications
2.9% vs. 14.3%, p  0.018). The incidence of these serious
omplications was also decreased when compared to both
ur initial 28 cases (2.9% vs. 39.3%, p  0.001), and the
ecently published cohort A of the PARTNER (Placement
f AoRTic TraNscathetER Valve Trial) United States
tudy (11.0%, p  0.043) where vascular closure was
erformed surgically. There was no significant difference in
he rate of minor complications (8.6% vs. 14.3%, p 0.305)
etween the late and early experience groups.
Prostar success and Prostar-related complications. Prostar-
related complications occurred in 13 cases (9.3%) and
included: 7 cases of insufficient hemostasis necessitating
balloon angioplasty (n  1), stent implantation (n  2) or
covered stent placement (n  4); 4 cases of significant
femoral artery stenosis necessitating balloon angioplasty;
and 2 femoral pseudoaneurysms treated by embolization
(n  1) or covered stent insertion (n  1). Notably, Prostar
failures were not associated with blood transfusion 4 U,
end-organ damage, or unplanned surgical closure, and thus
were classified as VARC minor complications. Prostar-
related complications were significantly reduced in the late
experience group compared with the early experience
group (4.3 vs. 14.3%, p  0.047).
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211Non–Prostar-related complications. Excluding Prostar fail-
res, femoral artery complications occurred in 10 cases
7.1%) and iliac complications in 5 cases (3.6%). Increasing
xperience was associated with a trend toward a lower rate of
liac complication (0% vs. 7.1%, p  0.058), but did not
ffect the frequency of femoral complications (7.1% vs.
.1%, p  1.000). Vascular intervention for non–Prostar-
elated complications was required in 17 patients (12.1%),
ncluding 5 patients (3.6%) who required emergent vas-
ular surgery. Among these cases, surgical intervention
as required in 2 iliac and 1 femoral artery ruptures, which
ere not controlled by covered stent placement, an external
liac artery vascular access, and a retroperitoneal hemorrhage.
here was a trend toward lower rate of any vascular interven-
ion (7.2% vs. 17.1%, p  0.119) in the late experience group.
Clinical outcome. The duration of intensive care unit stay
was significantly reduced with experience (3.3 2.1 days vs.
7.5  8.7 days, p  0.039). There was also a trend toward
Table 2. Procedural Characteristics of the Study Population
Total
(N140)
Early
Experience
(n70)
Late
Experience
(n70)
p
Value
Edwards valve 109 (77.9%) 52 (74.3%) 57 (81.4%) 0.416
CoreValve 31 (22.1%) 18 (25.7%) 13 (18.6%) 0.416
Local anesthesia 101 (71.4%) 33 (47.1%) 68 (97.1%) 0.001
Sheath size 19.6 2.3 20.9 2.5 18.4 1.1 0.001
18-F 63 (45.0%) 25 (35.7%) 38 (54.3%) 0.001
19-F 36 (25.7%) 5 (7.1%) 31 (44.3%)
22-F 23 (16.4%) 22 (31.4%) 1 (1.4%)
24-F 18 (12.9%) 18 (25.7%) 0 (%)
Introducer sheath outer
diameter, mm
7.72 0.83 8.15 0.80 7.28 0.55 0.001
Femoral artery MLD, mm 8.16 1.31 8.38 1.19 7.94 1.40 0.052
SFAR 0.96 0.14 0.99 0.12 0.94 0.16 0.068
SFAR 1.05 (%) 38 (27.3%) 21 (30.0%) 17 (24.6%) 0.478
Femoral artery calciﬁcation
score (0–3)
0.58 0.66 0.50 0.65 0.65 0.66 0.174
Femoral artery tortuosity
score (0–3)
0.25 0.51 0.19 0.43 0.32 0.58 0.126
Common iliac artery MLD, mm 10.45 2.30 11.11 2.58 9.76 1.75 0.001
External iliac artery MLD, mm 8.76 1.56 9.08 1.66 8.43 1.39 0.014
SEIAR 0.90 0.16 0.92 0.16 0.89 0.16 0.177
Iliac artery calciﬁcation
score (0–3)
1.02 0.86 0.93 0.79 1.12 0.93 0.202
Iliac artery tortuosity
score (0–3)
0.81 0.73 0.94 0.72 0.68 0.72 0.034
Number of Prostar XL used 1.30 0.49 1.59 0.52 1.00 0.17 0.001
Procedure time (skin to skin),
min
75.3 25.7 81.5 27.4 71.3 23.9 0.049
Fluoro time, min 20.7 10.9 20.8 10.2 20.6 11.3 0.919
Contrast volume, ml 140.8 49.0 143.0 46.7 139.1 50.9 0.689
Values are n (%) or mean SD.
MLD  minimal lumen diameter; SEIAR  sheath outer diameter/external iliac artery ratio;
SFAR sheath outer diameter/femoral artery ratio.horter in-hospital stay (8.5  3.9 days vs. 10.8  7.7 days, 0.100) in the late experience group compared with the
arly experience group (Table 3). The 30-day mortality rate
as 8.6%, and the 30-day combined safety endpoint oc-
urred in 17.9% of the study population. There was no
ignificant difference in the 30-day mortality (7.1% vs. 10.0%,
 0.563) or the 30-day combined safety endpoint (14.5% vs.
1.4%, p  0.378) between the groups.
Predictors of Prostar failure. Body mass index (BMI), fe-
ale sex, ACT, need for chronic anticoagulation, MLD of
Table 3. Prostar Success and Vascular Complications
Total
(N140)
Early
Experience
(n70)
Late
Experience
(n70) p Value
Any vascular complications 28 (20.0%) 20 (28.6%) 8 (11.4%) 0.012
VARC major complications 12 (8.6%) 10 (14.3%) 2 (2.9%) 0.018
VARC minor complications 16 (11.4%) 10 (14.3%) 6 (8.6%) 0.305
Any Blood transfusion 21 (15.0%) 11 (15.7%) 10 (14.3%) 1.000
Blood transfusion 4 U 3 (2.1%) 2 (2.9%) 1 (1.4%) 1.000
ICU stay, days 5.9 7.3 7.5 8.7 3.3 2.1 0.039
Hospital stay, days 10.3 7.2 10.8 7.7 8.5 3.9 0.100
30-day mortality 12 (8.6%) 7 (10.0%) 5 (7.1%) 0.563
30-day combined
safety endpoint
25 (17.9%) 15 (21.4%) 10 (14.5%) 0.378
Prostar failures and
related events
13 (9.3%) 10 (14.3%) 3 (4.3%) 0.047
Bleeding 7 (5.0%) 6 (8.6%) 1 (1.4%) 0.116
Balloon angioplasty 1 (0.7%) 1 (1.4%) 0 (0%) 1.000
Stent 2 (1.4%) 2 (2.9%) 0 (0%) 0.496
Covered stent 4 (2.9%) 3 (4.3%) 1 (1.4%) 0.620
Stenosis/occlusion 4 (2.9%) 3 (4.3%) 1 (1.4%) 0.620
Balloon angioplasty 4 (2.9%) 3 (4.3%) 1 (1.4%) 0.620
Pseudoaneurysm 2 (1.4%) 1 (1.4%) 1 (1.4%) 1.000
Embolization 1 (0.7%) 1 (1.4%) 0 (0%) 1.000
Covered stent 1 (0.7%) 0 (%) 1 (1.4%) 1.000
Non–Prostar-related events
Femoral events 10 (7.1%) 5 (7.1%) 5 (7.1%) 1.000
Rupture 2 (1.4%) 1 (1.4%) 1 (1.4%) 1.000
Dissection 4 (2.9%) 2 (2.9%) 2 (2.9%) 1.000
Stenosis/occlusion 1 (0.7%) 0 (0%) 1 (1.4%) 1.000
Pseudoaneurysm 1 (0.7%) 1 (1.4%) 0 (0%) 1.000
Hematoma 1 (0.7%) 1 (1.4%) 0 (0%) 1.000
Retroperitoneal bleeding 1 (0.7%) 0 (0%) 1 (1.4%) 1.000
Iliac artery events 5 (3.6%) 5 (7.1%) 0 (0%) 0.058
Rupture 3 (2.1%) 3 (4.3%) 0 (0%) 0.245
Dissection 2 (1.4%) 2 (2.9%) 0 (0%) 0.496
Local infection 0 (0%) 0 (0%) 0 (0%)
Vascular Intervention for
non–Prostar-related
complications
17 (12.1%) 12 (17.1%) 5 (7.2%) 0.119
Balloon angioplasty 4 (2.9%) 2 (2.9%) 2 (2.9%) 1.000
Femoral stenting 5 (3.6%) 3 (4.3%) 2 (2.9%) 1.000
Iliac stenting 3 (2.1%) 3 (4.3%) 0 0.245
Emergent vascular surgery 5 (3.6%) 4 (5.7%) 1 (1.4%) 0.366
Values are n (%) or mean SD.ICU intensive care unti; VARC valve academic research consortium.
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212femoral artery, sheath diameter, and valve type were not
associated with Prostar failure by univariate logistic regres-
sion analysis. Only early experience (hazard ratio [HR]:
3.66, 95% confidence interval [CI]: 1.04 to 13.89, p 
0.047) and the SFAR (HR: 110.8, 95% CI: 1.15 to
10,710.73, p  0.044) were predictive of Prostar failure
(Table 4). When patients treated with a 22- or 24-F sheath
were excluded, the SFAR was no longer a predictor of
Prostar failure (p  0.065). Previously, we have identified
the SFAR, experience, and femoral artery calcification as
independent predictors for vascular complications by mul-
tivariate analysis (3).
Discussion
This study describes the vascular complications and clinical
outcomes of consecutive transfemoral-TAVI cases per-
formed in a single center using a true percutaneous approach
with the Prostar XL vascular closure system. Our results
show a Prostar success rate of 90.7%, and VARC major and
minor vascular complications in 8.6% and 11.4% of patients,
respectively. The incidence of both Prostar failure and major
vascular complications is reduced by experience. The SFAR
is also a predictor of Prostar failure.
Potential advantages of a true percutaneous closure. The
introduction of TAVI in 2002 represented a highly signif-
icant development for patients diagnosed with severe inop-
erable or high surgical risk AS (20). Despite initial encour-
aging results, it was clear that this procedure required
development, to optimize patient outcomes. One such
refinement is the transition from surgical vascular access to
a true percutaneous approach. A true percutaneous proce-
dure, if performed appropriately, has the potential to reduce
the requirement for general or spinal anesthesia, shorten
procedure duration, reduce the risk of wound infections,
shorten post-operative patient immobilization and discom-
fort, and shorten the hospital stay (4).
Feasibility of a true percutaneous approach to transfemoral-TAVI.
Recently, a true percutaneous approach to transfemoral-
TAVI using the Prostar XL device has been described (21).
This device has been used extensively for vascular closure in
endovascular aortic aneurysm repair (5–11) and is known to
reduce procedure time and patient immobilization post-
operatively (4). Nevertheless, the Prostar XL may be asso-
ciated with vascular complications, particularly due to de-
Table 4. Predictors of Prostar Failure
Univariate
Variables Odds Ratio 95%CI p Value
Early experience 3.66 1.04–13.89 0.047
SFAR 110.80 1.15–10,710.73 0.044vCI confidence interval; SFAR sheath outer diameter/femoral artery ratio.ployment failure. To date, the reported rates of Prostar
failure (0% to 35.6%) and associated vascular complications
have varied considerably (5–14,22). A portion of this vari-
ability may be attributed to experience with the device. In
our study, Prostar failure occurred in 9.4% of cases, but this
was significantly reduced in the late experience compared
with the early experience cohort (4.3 vs. 14.3%, p  0.047).
ahlert et al. (12) reported a Prostar failure rate of 10% in
mixed cohort of Edwards and CoreValve patients, and
an Mieghem et al. (13) described a failure rate of 7.4% in
atients undergoing TAVI with the CoreValve (18-F).
Importantly, in our series, all Prostar failures were suc-
essfully managed without surgical intervention: balloon
ngioplasty (3.6%) or covered stent implantation (3.6%).
herefore, no Prostar failure was classified as a major
ascular complication according the recently published
ARC criteria (19). Nevertheless, vascular access and suc-
essful closure remain important issues in TAVI. Indeed,
he Prostar device has important limitations; the potential
or femoral artery stenosis or occlusion, puncture difficulty
n heavily calcified vessels, and a single device length that
ay result in increased failure in obese patients. The most
mportant factor may be the quality of the femoral arterial
uncture: common femoral artery, avoiding calcified
laques, and in the center of the artery. All these parameters
re related to the experience of the operator. Further
mprovements in patient outcome will be allied to optimal
creening, sheath downsizing, and the development of
ewer, operator friendly, vascular closure systems.
The reported incidence of vascular complications in
ransfemoral-TAVI series is highly variable (1,2,23–27). In
ur study, the rate of major and minor complications was
.6% and 11.4%, respectively. Major complications de-
reased significantly with experience: 14.3% in the early and
.9% in the late experience groups, respectively (p 0.018).
The incidence of these serious complications was also
decreased when compared with both our initial 28 cases
(2.9% vs. 39.3%, p  0.001), and the recently published
cohort A of PARTNER United States study (11.0%, p 
.043) where vascular closure was performed surgically.
Similar to the management of Prostar failures, most
ascular complications were successfully treated by endovas-
ular means, and only 5 patients (3.6%) required surgical
ntervention, and 4 cases of the 5 were observed in our early
xperience.
Our study suggests that experience plays an important
ole in the reduction of both Prostar failure and vascular
omplications. However, there were important differences
n the baseline characteristics of the early and late experience
roups, specifically an increased incidence of comorbid
onditions, and larger sheath size in the early experience
roup. However, these factors were not associated with
ncreased Prostar failures or vascular complications by uni-
ariate analysis.
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213Impact of experience on vascular complications. In this
series, the incidence of vascular complication was 20.0%.
We observed a significant reduction in the number of
vascular complication with experience (28.6% vs. 11.4%,
p  0.012). The incidence of major vascular complications
also decreased significantly from 14.3% to 2.9% (p 0.018),
presumably because of improved screening, patient selec-
tion, and device down-sizing.
This is in keeping with our previous report, which
identified experience as an independent predictor of major
vascular complications (3). Moreover, the incidence of iliac
complications, which is usually classified as a major com-
plication, also decreased with experience (0% vs. 7.1%, p 
0.058), probably due to better screening, including the use
of the SFAR parameter.
Predictors of Prostar failure. In this study, we identified 2
redictors of Prostar failure: early experience (HR: 3.66,
5% CI: 1.04 to 13.89, p  0.047) and a lower SFAR (HR:
10.8, 95% CI: 1.15 to 10,710.73, p 0.044). Eisenek et al.
5) have previously demonstrated that operator inexperience
as a predictor of Prostar failure in studies of endovascular
ortic aneurysm repair. There was a trend toward associa-
ion between Prostar failure and increased BMI (p 
.106). Arterial puncture in obese patients is technically
hallenging due to excess subcutaneous tissue and depth of
he femoral artery. Even with angiographic guidance, an
bese patient in our series required surgical arterial closure
ecause of cannulation of the external iliac artery. Not
urprisingly, morbid obesity has previously been identified
s a risk factor for complications of percutaneous femoral
rtery closure in patients undergoing endovascular aortic
neurysm repair (8,10).
We have previously described the SFAR as a predictor of
ARC major vascular complications. Interestingly, in this
eport, it also predicted Prostar failure. This index reflects
oth femoral artery diameter and size of the introducer
heath, and is a more powerful predictor of vascular events
han either of these criteria taken in isolation. We believe
hat the measurement of this simple ratio improves patient
election for transfemoral TAVI, and strongly recommend
ts routine application to avoid a considerable number of
ascular complications.
Minimally invasive strategy for transfemoral-TAVI. Although
he rapid evolution of transfemoral-TAVI has been associ-
ted with a reduction in complications and improved 30-day
ortality (1,2,24), these procedures remain high risk due to
he severity of complications that may occur in these frail
atients. In our study, using a true percutaneous approach
or transfemoral-TAVI, the combined safety endpoint oc-
urred in 17.9% of patients, with major and minor vascular
omplications in 20.0%, and a mean hospital stay of 10.3 
.2 days. Indeed, with increased experience, we observed a
eduction of 17.2% in the risk of all vascular complications,
ith associated reductions of 11.4% and 6.9% in the risk ofajor vascular complications and the combined 30-day
afety endpoint, respectively. Comparable results with this
trategy have been previously described (12). In the late
xperience group, transfemoral-TAVI was performed using
nly local anesthesia in 98.6% of cases, suggesting that these
nterventions are evolving into minimally invasive proce-
ures. However, the role of a multidisciplinary team ap-
roach, including cardiothoracic surgeons, general cardiol-
gists, and specialists in imaging, remains essential in the
election and management of TAVI recipients.
Study limitations. Our study reports on a single-center
transfemoral-TAVI cohort of limited size. We opted to
include patients who received the 22- and 24-F Edwards
sheaths, which are no longer commercially available, as they
were part of our initial experience. Multivariate analysis was
not performed because the low endpoint count of Prostar
failure precluded this analysis.
Further studies of larger patient populations are required
to confirm our results.
Conclusions
A true percutaneous approach in transfemoral-TAVI with
the Prostar XL vascular closure system was successfully
performed in 90.7% of cases. Experience plays a critical role
in successful true percutaneous approach in transfemoral-
TAVI, and predicts Prostar failure as well as SFAR does.
True percutaneous TAVI is feasible and is associated
with an acceptable risk of 30-day adverse events. Future
device development and minimally invasive techniques will
further improve outcome in these high-risk patients.
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